UK +44 (0) 203 929 0534 | US +1 (917) 297-6587

Lifecycle Management & Legacy Strategy

Our competitor has gone generic – how can we protect our own market share?

Our client has a key legacy asset in hematology which faces increasing pressure from generic forms of an alternative medication across multiple lines of therapy in EU5.

Eradigm used analogue benchmarking to evaluate the potential impact on our client’s drug sales, and identified optimal market-specific and cross-EU pricing and non-pricing strategies to preserve value for payers.

< Previous Case Study

Next Case Study >

Home                  Expertise                   Our Team                   Join us                    Contact us

Brand & Website design by GeoMedia           Privacy Policy

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Home                  Expertise                   Our Team                   Join Us                    Contact Us

Home                  Expertise                   Our Team
Join Us                    Contact Us

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Brand & Website design by GeoMedia          Privacy Policy